All In Biotech

Drug Trial Radar · NCT02282813

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 298 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

298

Actual

Start

Apr 2013

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Nov 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.

Conditions

  • Chronic Kidney Disease
  • Hyperparathyroidism, Secondary
  • Vitamin D Deficiency

Interventions

  • CTAP101 CapsulesDrug

    At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

  • CalcitriolDrug

    At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily

  • DoxercalciferolDrug

    At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily

  • ParicalcitolDrug

    At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)Time frame: up to 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.